TRAW Stock — Traws Pharma Inc.: Cash, EV, Pipeline

What they do

We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.22

Market cap

$3.4M

Cash

$3.9M

Enterprise value

-$0.5M

Balance sheet

Cash	$3.9M
Debt	$0.0M
Net cash	$3.9M
Enterprise value	-$0.5M
Basic shares	15.4M shares
Fully diluted shares	55.6M shares
Fully diluted market cap	$12.2M
Cash per share	$0.25
Quarterly burn	$7.5M
Cash runway	0.5 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

15.4M

Pre-funded warrants

0.0M

Options

2.0M

RSUs

0.0M

Warrants

35.5M

Converts

0.0M

Conv preferred

2.7M

ESPP reserve

—

FDSO

55.6M

Cap table as of 2026-06-30.

Price history

Loading TRAW daily closes…

Loading price history…

Next catalyst

TRX-100 · Now - Nov 24, 2026 Now · Phase 1 · Healthy Volunteer

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	TRX-100	Phase 1	Healthy Volunteer	—
Dec 13, 2026 - Jan 24, 2027 in 5 wks	TRX-100	Phase 2	Influenza	—
Jan 12 - Feb 23 in 9 wks	TRX-100	Phase 2	Influenza	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Tivoxavir marboxil

Phase 1 · Active Modality: small molecule

Aliases TXM

Target cap-dependent endonuclease (CEN)

Indications

Bird flu (H5N1) and seasonal influenza (Phase 1)

Catalysts

— third quarter of 2026
— by the end of 2026

Status note Single-dose oral CEN inhibitor. Phase 1 completed in Australia; proposed Phase 2 dose-ranging and Phase 2a human challenge studies deferred. US IND on clinical hold (toxicology data package); UK MHRA challenge study deferred Jun 2026 pending toxicology resubmission. Acquired via Trawsfynydd merger Apr 2024.

Ratutrelvir

Phase 2 · Active Modality: small molecule

Aliases TRX01

Target SARS-CoV-2 main protease (3CL)

Indications

COVID-19 (Phase 2)

Status note Phase 1 completed Sep 2024 (Australia); Phase 2a completed. Intended for use without a CYP inhibitor such as ritonavir. Acquired via Trawsfynydd merger Apr 2024.

Narazaciclib

Phase 2 · Active Modality: small molecule

Aliases ON 123300

Target CDK4 (plus CDK, AMPK, ARK5, CSF1R)

Indications

Endometrial cancer (low-grade endometrioid, with letrozole) (Phase 2)
Advanced solid tumors / hematologic malignancies (Phase 1)

Status note Oral CDK4-plus multi-targeted kinase inhibitor. Phase 1/2a trial in endometrial cancer closed to accrual (database locked); monotherapy Phase 1 in advanced cancer closed. No further company-sponsored development; oncology assets limited to business development/out-licensing.

Rigosertib

Stage not disclosed · Active

Target PLK1

Indications

Epidermolysis bullosa-associated squamous cell carcinoma (Stage not disclosed)

Status note Legacy Onconova asset; studied only in investigator-initiated trials (IV or oral); limited to business development/out-licensing. Symbio license agreement mutually terminated Apr 17, 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Ratutrelvir (83-0060) non-randomised
Lead indication	COVID - 19
Lead phase	Phase 2
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07503405	Phase 2	Not yet recruiting	Sponsor	TRAW	—	Influenza	—
NCT07371650	Phase 2	Active, not recruiting	Sponsor	TRAW	—	Influenza	—
NCT07157007	Phase 2	Recruiting	Sponsor	TRAW	—	COVID - 19	—
NCT07526506	Phase 1	Recruiting	Sponsor	TRAW	—	Healthy Volunteer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Traws Pharma, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	1,203,260	+597,729	0.02%	2026-08-14
Ally Bridge Group	786,236	+786,236	0.85%	2026-08-14
ADAR1 Capital Management	597,729	+443,631	0.02%	2026-08-14
Ikarian Capital	478,142	-200,000	0.07%	2026-08-14
Sphera Biotech	398,486	+398,486	0.05%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

TRAW — Traws Pharma Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

TRAW — Traws Pharma Inc.